Elicio

1 known investors

Elicio develops cancer immunotherapies including vaccines, immunomodulators, and adjuvants built on its lymph node-targeted AMP platform to activate and amplify cancer-fighting T cells. The company focuses on treating solid tumors, particularly pancreatic ductal adenocarcinoma (PDAC).